We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Stock Moves -1.47%: What You Should Know
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed at $73.65 in the latest trading session, marking a -1.47% move from the prior day. This change was narrower than the S&P 500's daily loss of 1.57%. Meanwhile, the Dow lost 1.56%, and the Nasdaq, a tech-heavy index, lost 0.09%.
Coming into today, shares of the vaccine maker had lost 13.47% in the past month. In that same time, the Medical sector gained 5.64%, while the S&P 500 gained 5.37%.
Investors will be hoping for strength from Novavax as it approaches its next earnings release. On that day, Novavax is projected to report earnings of $3.30 per share, which would represent year-over-year growth of 208.2%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $888.11 million, up 98.58% from the year-ago period.
NVAX's full-year Zacks Consensus Estimates are calling for earnings of $22.84 per share and revenue of $4.57 billion. These results would represent year-over-year changes of +197.44% and +298.65%, respectively.
Any recent changes to analyst estimates for Novavax should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 9.6% lower within the past month. Novavax is currently sporting a Zacks Rank of #4 (Sell).
Looking at its valuation, Novavax is holding a Forward P/E ratio of 3.27. For comparison, its industry has an average Forward P/E of 22.96, which means Novavax is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 162, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Stock Moves -1.47%: What You Should Know
Novavax (NVAX - Free Report) closed at $73.65 in the latest trading session, marking a -1.47% move from the prior day. This change was narrower than the S&P 500's daily loss of 1.57%. Meanwhile, the Dow lost 1.56%, and the Nasdaq, a tech-heavy index, lost 0.09%.
Coming into today, shares of the vaccine maker had lost 13.47% in the past month. In that same time, the Medical sector gained 5.64%, while the S&P 500 gained 5.37%.
Investors will be hoping for strength from Novavax as it approaches its next earnings release. On that day, Novavax is projected to report earnings of $3.30 per share, which would represent year-over-year growth of 208.2%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $888.11 million, up 98.58% from the year-ago period.
NVAX's full-year Zacks Consensus Estimates are calling for earnings of $22.84 per share and revenue of $4.57 billion. These results would represent year-over-year changes of +197.44% and +298.65%, respectively.
Any recent changes to analyst estimates for Novavax should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 9.6% lower within the past month. Novavax is currently sporting a Zacks Rank of #4 (Sell).
Looking at its valuation, Novavax is holding a Forward P/E ratio of 3.27. For comparison, its industry has an average Forward P/E of 22.96, which means Novavax is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 162, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.